HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An attenuated EIAV vaccine strain induces significantly different immune responses from its pathogenic parental strain although with similar in vivo replication pattern.

Abstract
The EIAV (equine infectious anemia virus) multi-species attenuated vaccine EIAV(DLV121) successfully prevented the spread of equine infectious anemia (EIA) in China in the 1970s and provided an excellent model for the study of protective immunity to lentiviruses. In this study, we compared immune responses induced by EIAV(DLV121) to immunity elicited by the virulent EIAV(LN40) strain and correlated immune responses to protection from infection. Horses were randomly grouped and inoculated with either EIAV(DLV121) (Vaccinees, Vac) or a sublethal dose of EIAV(LN40) (asymptomatic carriers, Car). Car horses became EIAV(LN40) carriers without disease symptoms. Two of the four Vac horses were protected against infection and the other two had delayed onset or reduced severity of EIA with a lethal EIAV(LN40) challenge 5.5 months post initial inoculation. In contrast, all three Car animals developed acute EIA and two succumbed to death. Specific humoral and cellular immune responses in both Vac and Car groups were evaluated for potential correlations with protection. These analyses revealed that although plasma viral loads remained between 10(3) and 10(5)copies/ml for both groups before EIAV(LN40) challenge, Vac-treated animals developed significantly higher levels of conformational dependent, Env-specific antibody, neutralizing antibody as well as significantly elevated CD4(+) T cell proliferation and IFN-γ-secreting CD8(+) T cells than those observed in EIAV(LN40) asymptomatic carriers. Further analysis of protected and unprotected cases in vaccinated horses identified that cellular response parameters and the reciprocal anti-p26-specific antibody titers closely correlated with protection against infection with the pathogenic EIAV(LN40). These data provide a better understanding of protective immunity to lentiviruses.
AuthorsYue-Zhi Lin, Rong-Xian Shen, Zhen-Ying Zhu, Xi-Lin Deng, Xue-Zhi Cao, Xue-Feng Wang, Jian Ma, Cheng-Gang Jiang, Li-Ping Zhao, Xiao-Ling Lv, Yi-Ming Shao, Jian-Hua Zhou
JournalAntiviral research (Antiviral Res) Vol. 92 Issue 2 Pg. 292-304 (Nov 2011) ISSN: 1872-9096 [Electronic] Netherlands
PMID21893100 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 Elsevier B.V. All rights reserved.
Chemical References
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Viral Proteins
  • Viral Vaccines
  • Interferon-gamma
Topics
  • Animals
  • Antibodies, Neutralizing (blood)
  • Antibodies, Viral (blood)
  • CD4-Positive T-Lymphocytes (immunology)
  • CD8-Positive T-Lymphocytes (immunology)
  • Cell Proliferation
  • China
  • Equine Infectious Anemia (immunology, pathology, prevention & control)
  • Female
  • Horses
  • Infectious Anemia Virus, Equine (growth & development, immunology)
  • Interferon-gamma (metabolism)
  • Male
  • Viral Load
  • Viral Proteins (immunology)
  • Viral Vaccines (administration & dosage, immunology)
  • Viremia

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: